DAJH-1050766

DAJH-1050766 is a small molecule tyrosine kinase inhibitor (TKI) targeting the mesenchymal-epithelial transition (MET) receptor, also known as hepatocyte growth factor receptor (HGFR). Developed by Chengdu Diao Jiuhong Pharmaceutical Factory, it is currently being evaluated in clinical trials for the treatment of advanced solid tumors and non-small cell lung cancer (NSCLC), specifically focusing on patients with MET exon 14 skipping mutations. By selectively binding to the MET kinase domain, DAJH-1050766 inhibits MET phosphorylation and its downstream signaling cascades, which are often dysregulated in various cancers to promote tumor cell proliferation, survival, and invasion. The drug is administered orally and represents a targeted therapy approach for MET-driven malignancies.